Search hospitals > Pennsylvania > West Chester
Chester County Hospital
Claim this profileWest Chester, Pennsylvania 19380
Global Leader in Parotid Gland Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Breast cancer
Conducts research for Cervical Adenocarcinoma
95 reported clinical trials
3 medical researchers
Summary
Chester County Hospital is a medical facility located in West Chester, Pennsylvania. This center is recognized for care of Parotid Gland Cancer, Breast Cancer, Lung Cancer, Breast cancer, Cervical Adenocarcinoma and other specialties. Chester County Hospital is involved with conducting 95 clinical trials across 179 conditions. There are 3 research doctors associated with this hospital, such as William E. Luginbuhl, Maureen Hewitt, MD, and Andre A. Konski.Area of expertise
1Parotid Gland Cancer
Global LeaderStage III
Stage IV
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
PR positive
Top PIs
William E. LuginbuhlChester County Hospital5 years of reported clinical research
Studies Parotid Gland Cancer
Studies Ovarian Cancer
14 reported clinical trials
50 drugs studied
Maureen Hewitt, MDChester County Hospital5 years of reported clinical research
Studies Breast Cancer
Studies Parotid Gland Cancer
12 reported clinical trials
24 drugs studied
Andre A. KonskiChester County Hospital4 years of reported clinical research
Studies Prostate Adenocarcinoma
Studies Prostate Cancer
5 reported clinical trials
18 drugs studied
Clinical Trials running at Chester County Hospital
Lung Cancer
Prostate Cancer
Breast Cancer
Uterine Cancer
Rectal Cancer
Pancreatic Cancer
Parotid Gland Cancer
Non-Small Cell Lung Cancer
Prostate Adenocarcinoma
Cervical Adenocarcinoma
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Chester County Hospital?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.